HCPLive 5 Stories in Under 5: Week of 04/27

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

Interested in a more traditional, text rundown? Check out the HCPFive!

Top 5 Healthcare Headlines for April 21-27, 2025:

FDA Approves Pz-cel (Zevaskyn) Gene Therapy for RDEB
The FDA has approved pz-cel, the first autologous gene therapy for RDEB, following pivotal Phase 3 data demonstrating efficacy and safety in wound healing.

FDA Approves Upadacitinib, Expanding Treatment for Adults With Giant Cell Arteritis
Upadacitinib has been approved for giant cell arteritis, supported by Phase 3 data showing its potential to induce sustained remission and reduce corticosteroid reliance.

FDA Approves Nipocalimab Generalized Myasthenia Gravis for Adults, Children
Nipocalimab received FDA approval for gMG in antibody-positive patients aged ≥12, expanding therapeutic options across major serotypes.

Semaglutide Improves Steatohepatitis, Fibrosis in Phase 3 MASH Trial
Phase 3 trial results show semaglutide significantly improves steatohepatitis and fibrosis markers in patients with MASH, without worsening liver histology.

Increased Fasting Blood Glucose Triples Risk of Heart Damage in Adolescents
International data links elevated fasting glucose and insulin resistance in adolescence to markedly increased future risk of heart damage, especially among females.